Opinion

Video

Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma

Ke Ning, MD, discusses the impact of the introduction of bispecific antibodies for treating patients with relapsed or refractory multiple myeloma.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
1 expert in this video
1 expert in this video
Pharmacy Times OPC
5 experts in this video
1 expert is featured in this series.
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue.
5 experts in this video
5 experts in this video